Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and...

Full description

Bibliographic Details
Main Authors: Kent Y. Feng, MD, Rahul S. Loungani, MD, Vishal N. Rao, MD, MPH, Chetan B. Patel, MD, Michel G. Khouri, MD, G. Michael Felker, MD, MHS, Adam D. DeVore, MD, MHS
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:JACC. CardioOncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087319300912